“Abstract: … Very recently in Bangladesh, a group of doctors reported astounding success in treating patients suffering from COVID-19 with two commonly used drugs, Ivermectin and Doxycycline. In the current study we have explored the possible mechanism by which these drugs might have worked for the positive response in the COVID-19 patients… Our study shows that both Ivermectin and doxycycline have significantly bind with SARS-CoV-2 proteins but Ivermectin was better binding than doxycycline. Ivermectin showed a perfect binding site to the Spike-RBD and ACE2 interacting region indicating that it might be interfering in the interaction of spike with ACE2 and preventing the viral entry in to the host cells. Ivermectin also exhibited significant binding affinity with different SARS-CoV-2 structural and non-structural proteins (NSPs) which have diverse functions in virus life cycle. Significant binding of Ivermectin with RdRp indicate its role in the inhibition of the viral replication and ultimately impeding the multiplication of the virus. Ivermectin also possess significant binding affinity with NSP3, NSP10, NSP15 and NSP16 which helps virus in escaping from host immune system. Molecular dynamics simulation study shows that binding of the Ivermectin with Mpro, Spike, NSP3, NSP16 and ACE2 was quiet stable. Thus, our docking and simulation studies reveal that combination of Ivermectin and doxycycline might be executing the effect by inhibition of viral entry and enhance viral load clearance by targeting various viral functional proteins…
In summary, the miraculous effect of combination of Ivermectin and doxycycline in COVID-19 patients is possibly by inhibition of spike-ACE2 interaction and inhibiting RNA dependent RNA polymerase, ADP Ribose Phosphatase, Endoribonuclease and NSP10-NSP16 complex mediated methyltransferase activities, anti-viral activity and chelation of the zinc & immunomodulatory property. Thus, the usage of Ivermectin and doxycycline combination will be an ideal choice in prevention and management of COVID-19.”
"Is Cambridge Open Engage content peer reviewed? No. The platform is an early research space and only content that has not yet been accepted for publication in a peer-reviewed journal, book, or other format can be uploaded (though content can remain on the platform after acceptance and publication have taken place). Research content uploaded can subsequently be submitted to Cambridge University Press journals for peer review. In due course, corresponding authors will be able to submit directly from the platform to selected Cambridge University Press journal titles. Uploads to the site pass through a series of key checks for plagiarism and other issues, and also for general appropriateness using the criteria detailed above."
Source: https://www.cambridge.org/engage/coe/contact-information?show=faqs
All content on Cambridge Open Engage is freely available and can be shared by the corresponding author or coauthor(s) without any need to request permission."
Source: https://www.cambridge.org/engage/coe/contact-information?show=faqs